Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University College, London
The First Hospital of Jilin University
Ohio State University Comprehensive Cancer Center
University of Wisconsin, Madison
National Institutes of Health Clinical Center (CC)
Henan Cancer Hospital
Centre Antoine Lacassagne
Institut Bergonié
University Hospital Southampton NHS Foundation Trust
National Institutes of Health Clinical Center (CC)
SWOG Cancer Research Network
University of Chicago
Henan Cancer Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
The First Affiliated Hospital with Nanjing Medical University
Hoffmann-La Roche
University of Nebraska
Liaoning Cancer Hospital & Institute
Eastern Cooperative Oncology Group
Celgene
National Institutes of Health Clinical Center (CC)
University of Birmingham
National Institutes of Health Clinical Center (CC)
Rush University Medical Center
IRCCS San Raffaele
Innovent Biologics (Suzhou) Co. Ltd.
The First Affiliated Hospital with Nanjing Medical University
Institute of Hematology & Blood Diseases Hospital, China
SWOG Cancer Research Network
Medstar Health Research Institute
Universität des Saarlandes
Universität des Saarlandes
Ruijin Hospital
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Kosin University Gospel Hospital
Alliance for Clinical Trials in Oncology
Seagen Inc.
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Seagen Inc.
AIDS Malignancy Consortium
Ohio State University Comprehensive Cancer Center
Ruijin Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Miami
National Cancer Institute (NCI)
SWOG Cancer Research Network
Takeda
Memorial Sloan Kettering Cancer Center